BusinessAdaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma StudyBy Nasdaq OMXDec 5, 2016, 12:30 PM UTC
BusinessAdaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple MyelomaBy Nasdaq OMXOct 27, 2016, 2:05 PM UTC
BusinessAdaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10By Nasdaq OMXOct 18, 2016, 12:00 PM UTC
BusinessAdaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian CancerBy Nasdaq OMXOct 12, 2016, 1:15 PM UTC
BusinessAdaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver CancerBy Nasdaq OMXApr 7, 2016, 1:03 PM UTC
BusinessU.S. Food and Drug Administration Grants Orphan Drug Designation to Adaptimmune’s T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue SarcomaBy Nasdaq OMXMar 30, 2016, 11:40 AM UTC
BusinessAdaptimmune Reports Financial Results for the Six-Month Period ended December 31, 2015By Nasdaq OMXMar 17, 2016, 11:56 AM UTC
BusinessU.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune’s Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial SarcomaBy Nasdaq OMXFeb 9, 2016, 4:59 PM UTC
